FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans Huber

Research Profile

Concepts & Ideas

Chemicals & Drugs

Anatomy

Genes & Molecular Sequences

Molecular Structure

Phenomena

Phosphorylation

Physiology

Occupations

Drug Design

Co-author Network

Publications

TOP 3
Craig Cherrin; Kathleen M Haskell; Bonnie Howell; Raymond Jones; Karen Leander; Ronald Robinson; Aubrey Watkins; Mark Bilodeau; Jacob Hoffman; Philip Sanderson; George Hartman; Elizabeth Mahan; Thomayant Prueksaritanont; Guoqiang Jiang; Qing-Bai She; Neal Rosen; Laura Sepp-Lorenzino; Deborah DeFeo-Jones; Hans E Huber
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Miguel Aste-Amézaga; Ningyan Zhang; Janet E Lineberger; Beth A Arnold; Timothy J Toner; Mingcheng Gu; Lingyi Huang; Salvatore Vitelli; Kim T Vo; Peter Haytko; Jing Zhang Zhao; Frederic Baleydier; Sarah L'Heureux; Hongfang Wang; Wendy R Gordon; Elizabeth Thoryk; Marie Blanke Andrawes; Kittichoat Tiyanont; Kimberly Stegmaier; Giovanni Roti; Kenneth N Ross; Laura L Franlin; Hui Wang; Fubao Wang; Michael Chastain; Andrew J Bett; Laurent P Audoly; Jon C Aster; Stephen C Blacklow; Hans E Huber
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Yiwei Li; Jun Liang; Tony Siu; Essa Hu; Michael A Rossi; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; Ronald G Robinson; Karen Leander; Hans E Huber; Sachin Mittal; Nicholas Cosford; Peppi Prasit
Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans Huber (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Craig Cherrin; Kathleen M Haskell; Bonnie Howell; Raymond Jones; Karen Leander; Ronald Robinson; Aubrey Watkins; Mark Bilodeau; Jacob Hoffman; Philip Sanderson; George Hartman; Elizabeth Mahan; Thomayant Prueksaritanont; Guoqiang Jiang; Qing-Bai She; Neal Rosen; Laura Sepp-Lorenzino; Deborah DeFeo-Jones; Hans E Huber
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cancer biology & therapy 2010;9(7):493-503.
2010: Miguel Aste-Amézaga; Ningyan Zhang; Janet E Lineberger; Beth A Arnold; Timothy J Toner; Mingcheng Gu; Lingyi Huang; Salvatore Vitelli; Kim T Vo; Peter Haytko; Jing Zhang Zhao; Frederic Baleydier; Sarah L'Heureux; Hongfang Wang; Wendy R Gordon; Elizabeth Thoryk; Marie Blanke Andrawes; Kittichoat Tiyanont; Kimberly Stegmaier; Giovanni Roti; Kenneth N Ross; Laura L Franlin; Hui Wang; Fubao Wang; Michael Chastain; Andrew J Bett; Laurent P Audoly; Jon C Aster; Stephen C Blacklow; Hans E Huber
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
PloS one 2010;5(2):e9094.
2009: Yiwei Li; Jun Liang; Tony Siu; Essa Hu; Michael A Rossi; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; Ronald G Robinson; Karen Leander; Hans E Huber; Sachin Mittal; Nicholas Cosford; Peppi Prasit
Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Bioorganic & medicinal chemistry letters 2009;19(3):834-6.
2008: Christopher D Cox; Paul J Coleman; Michael J Breslin; David B Whitman; Robert M Garbaccio; Mark E Fraley; Carolyn A Buser; Eileen S Walsh; Kelly Hamilton; Michael D Schaber; Robert B Lobell; Weikang Tao; Joseph P Davide; Ronald E Diehl; Marc T Abrams; Vicki J South; Hans E Huber; Maricel Torrent; Thomayant Prueksaritanont; Chunze Li; Donald E Slaughter; Elizabeth A Mahan; Carmen Fernandez-Metzler; Youwei Yan; Lawrence C Kuo; Nancy E Kohl; George D Hartman
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Journal of medicinal chemistry 2008;51(14):4239-52.
2008: Mark T Bilodeau; Adrienne E Balitza; Jacob M Hoffman; Peter J Manley; Stanley Barnett; Deborah DeFeo-Jones; Kathleen Haskell; Raymond E Jones; Karen Leander; Ronald G Robinson; Anthony M Smith; Hans E Huber; George D Hartman
Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bioorganic & medicinal chemistry letters 2008;18(11):3178-82.
2008: Zhicai Wu; Ronald G Robinson; Sheng Fu; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; Astrid M Kral; Hans E Huber; Nancy E Kohl; George D Hartman; Mark T Bilodeau
Rapid assembly of diverse and potent allosteric Akt inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(6):2211-4.
2008: John C Hartnett; Stanley Barnett; Mark T Bilodeau; Deborah DeFeo-Jones; George D Hartman; Hans E Huber; Raymond E Jones; Astrid M Kral; Ronald G Robinson; Zhicai Wu
Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(6):2194-7.
2008: Zhicai Wu; John C Hartnett; Lou Anne Neilson; Ronald G Robinson; Sheng Fu; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; Astrid M Kral; Hans E Huber; George D Hartman; Mark T Bilodeau
Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(4):1274-9.
2008: Qing-Bai She; Sarat Chandarlapaty; Qing Ye; Jose Lobo; Kathleen M Haskell; Karen R Leander; Deborah DeFeo-Jones; Hans E Huber; Neal Rosen
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PloS one 2008;3(8):e3065.
2008: Zhijian Zhao; Ronald G Robinson; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; George D Hartman; Hans E Huber; Mark E Duggan; Craig W Lindsley
Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.
Bioorganic & medicinal chemistry letters 2008;18(1):49-53.
2007: Robert M Garbaccio; Edward S Tasber; Lou Anne Neilson; Paul J Coleman; Mark E Fraley; Christy Olson; Jeff Bergman; Maricel Torrent; Carolyn A Buser; Keith Rickert; Eileen S Walsh; Kelly Hamilton; Robert B Lobell; Weikang Tao; Vicki J South; Ronald E Diehl; Joseph P Davide; Youwei Yan; Lawrence C Kuo; Chunze Li; Thomayant Prueksaritanont; Carmen Fernandez-Metzler; Elizabeth A Mahan; Donald E Slaughter; Joseph J Salata; Nancy E Kohl; Hans E Huber; George D Hartman
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2007;17(20):5671-6.
2007: Christopher D Cox; Michael J Breslin; David B Whitman; Paul J Coleman; Robert M Garbaccio; Mark E Fraley; Matthew M Zrada; Carolyn A Buser; Eileen S Walsh; Kelly Hamilton; Robert B Lobell; Weikang Tao; Marc T Abrams; Vicki J South; Hans E Huber; Nancy E Kohl; George D Hartman
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Bioorganic & medicinal chemistry letters 2007;17(10):2697-702.
2006: Mark E Fraley; Robert M Garbaccio; Kenneth L Arrington; William F Hoffman; Edward S Tasber; Paul J Coleman; Carolyn A Buser; Eileen S Walsh; Kelly Hamilton; Christine Fernandes; Michael D Schaber; Robert B Lobell; Weikang Tao; Vicki J South; Youwei Yan; Lawrence C Kuo; Thomayant Prueksaritanont; Cathy Shu; Maricel Torrent; David C Heimbrook; Nancy E Kohl; Hans E Huber; George D Hartman
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2006;16(7):1775-9.
2006: Robert M Garbaccio; Mark E Fraley; Edward S Tasber; Christy M Olson; William F Hoffman; Kenneth L Arrington; Maricel Torrent; Carolyn A Buser; Eileen S Walsh; Kelly Hamilton; Michael D Schaber; Christine Fernandes; Robert B Lobell; Weikang Tao; Vicki J South; Youwei Yan; Lawrence C Kuo; Thomayant Prueksaritanont; Donald E Slaughter; Cathy Shu; David C Heimbrook; Nancy E Kohl; Hans E Huber; George D Hartman
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Bioorganic & medicinal chemistry letters 2006;16(7):1780-3.
2005: Christopher D Cox; Michael J Breslin; Brenda J Mariano; Paul J Coleman; Carolyn A Buser; Eileen S Walsh; Kelly Hamilton; Hans E Huber; Nancy E Kohl; Maricel Torrent; Youwei Yan; Lawrence C Kuo; George D Hartman
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2005;15(8):2041-5.
2005: Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan; Craig W Lindsley
Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.
Bioorganic & medicinal chemistry letters 2005;15(4):905-9.
2005: Deborah DeFeo-Jones; Stanley Barnett; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Karen Leander; Elizabeth McAvoy; Ronald G Robinson; Mark E Duggan; Craig W Lindsley; Zhijian Zhao; Hans E Huber; Raymond E Jones
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
Molecular cancer therapeutics 2005;4(2):271-9.
2005: Craig W Lindsley; Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley Barnett; Deborah DeFeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.
Bioorganic & medicinal chemistry letters 2005;15(3):761-4.
2005: Stanley Barnett; Deborah DeFeo-Jones; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Raymond E Jones; Jason A Kahana; Astrid M Kral; Karen Leander; Ling L Lee; John Malinowski; Elizabeth McAvoy; Debbie D Nahas; Ronald G Robinson; Hans E Huber
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.
The Biochemical journal 2005;385(Pt 2):399-408.
2004: Christopher Dinsmore; C Blair Zartman; Jeffrey M Bergman; Marc T Abrams; Carolyn A Buser; J Christopher Culberson; Joseph P Davide; Michelle Ellis-Hutchings; Christine Fernandes; Samuel L Graham; George D Hartman; Hans E Huber; Robert B Lobell; Scott D Mosser; Ronald G Robinson; Theresa M Williams
Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorganic & medicinal chemistry letters 2004;14(3):639-43.
2004: Youwei Yan; Vinod Sardana; Bei Xu; Carl F Homnick; Wasyl Halczenko; Carolyn A Buser; Michael D Schaber; George D Hartman; Hans E Huber; Lawrence C Kuo
Inhibition of a mitotic motor protein: where, how, and conformational consequences.
Journal of molecular biology 2004;335(2):547-54.
2003: S Jane deSolms; Terrence M Ciccarone; Suzanne C MacTough; Anthony W Shaw; Carolyn A Buser; Michelle Ellis-Hutchings; Christine Fernandes; Kelly A Hamilton; Hans E Huber; Nancy E Kohl; Robert B Lobell; Ronald G Robinson; Nancy N Tsou; Eileen S Walsh; Samuel L Graham; Lorena S Beese; Jeffrey S Taylor
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
Journal of medicinal chemistry 2003;46(14):2973-84.
2002: Thomas J Tucker; Marc T Abrams; Carolyn A Buser; Joseph P Davide; Michelle Ellis-Hutchings; Christine Fernandes; Jackson B Gibbs; Samuel L Graham; George D Hartman; Hans E Huber; Dongming Liu; Robert B Lobell; William C Lumma; Ronald G Robinson; John T Sisko; Anthony M Smith
The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.
Bioorganic & medicinal chemistry letters 2002;12(15):2027-30.
2002: Diem N Nguyen; Craig A Stump; Eileen S Walsh; Christine Fernandes; Joseph P Davide; Michelle Ellis-Hutchings; Ronald G Robinson; Theresa M Williams; Robert B Lobell; Hans E Huber; Carolyn A Buser
Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorganic & medicinal chemistry letters 2002;12(9):1269-73.
2001: Hans E Huber; Ronald G Robinson; A Watkins; D D Nahas; Marc T Abrams; Carolyn A Buser; Robert B Lobell; D Patrick; Neville J Anthony; Christopher Dinsmore; Samuel L Graham; George D Hartman; William C Lumma; Theresa M Williams; David C Heimbrook
Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors.
The Journal of biological chemistry 2001;276(27):24457-65.
2001: Jeffrey M Bergman; Marc T Abrams; Joseph P Davide; IB Greenberg; Ronald G Robinson; Carolyn A Buser; Hans E Huber; Kenneth S Koblan; Nancy E Kohl; Robert B Lobell; Samuel L Graham; George D Hartman; Theresa M Williams; Christopher Dinsmore
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorganic & medicinal chemistry letters 2001;11(11):1411-5.
2001: Wes Trotter; Amy G Quigley; William C Lumma; John T Sisko; Eileen S Walsh; C S Hamann; Ronald G Robinson; HG Bhimnathwala; D G Kolodin; W Zheng; Carolyn A Buser; Hans E Huber; Robert B Lobell; Nancy E Kohl; Theresa M Williams; Samuel L Graham; Christopher Dinsmore
2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry letters 2001;11(7):865-9.
2001: Christopher Dinsmore; Michael J Bogusky; J Christopher Culberson; Jeffrey M Bergman; Carl F Homnick; C Blair Zartman; Scott D Mosser; Michael D Schaber; Ronald G Robinson; Kenneth S Koblan; Hans E Huber; Samuel L Graham; George D Hartman; Joel R Huff; Theresa M Williams
Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
Journal of the American Chemical Society 2001;123(9):2107-8.